Estrogen improves vascular function via peroxisome-proliferator-activated-receptor-γ

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 2, 2012, Pages 268-276

  Tiyerili, Vedat ^a   Müller, Cornelius F H ^a   Fung, Stephen ^a   Panek, Darius ^a   Nickenig, Georg ^a   Becher, Ulrich M ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Atherosclerosis; Inflammation; Sex hormones; Vasculature; Women

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ESTRADIOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; ATHEROGENESIS; ATHEROPROTECTIVE ACTIVITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ENZYME REGULATION; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; MONOCYTE; MORPHOLOGY; MOUSE; NONHUMAN; OVARIECTOMY; OVARY FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM;

ANILIDES; ANIMALS; APOLIPOPROTEINS E; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; ESTRADIOL; ESTROGENS; FEMALE; HEART RATE; IMMUNOHISTOCHEMISTRY; MICE; PPAR GAMMA; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; SUPEROXIDES; THIAZOLIDINEDIONES;

MUS;

EID: 84862855753     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.05.008     Document Type: Article

References (34)

1. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987, 316:1105-1110.
2. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993, 328:1069-1075.
3. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308:1583-1587.
4. Hodgin J.B., Maeda N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 2002, 143:4495-4501.
5. Caulin-Glaser T., Watson C.A., Pardi R., Bender J.R. Effects of 17-ß-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996, 98:36-42.
6. Nickenig G., Baumer A.T., Grohe C., Kahlert S., Strehlow K., Rosenkranz S., et al. Estrogen modulates AT1-receptor gene expression in vitro and in vivo. Circulation 1998, 97:2197-2201.
7. Wagner J.D., Clarkson T.B., St Clair R.W., Schwenke D.C., Shively C.A., Adams M.R. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991, 88(6):1995-2002.
8. Babaev V.R., Yancey P.G., Ryzhov S.V., Kon V., Breyer M.D., Magnuson M.A., et al. Conditional knockout of macrophage PPARg increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25:1647-1653.
9. Hamblin M., Chang L., Zhang H., Yang K., Zhang J., Chen Y.E. Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation. Arterioscler Thromb Vasc Biol 2011 Feb, 31(2):352-359.
10. Qu A., Shah Y.M., Manna S.K., Gonzalez F.J. Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2012, 32(1):65-73.
11. Karas R.H., Schulten H., Pare G., Aronovitz M.J., Ohlsson C., Gustafsson J.A. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 2001, 89:534-539.
12. Murphy A.J., Guyre P.M., Wira C.R., Pioli P.A. Estradiol regulates expression of estrogen receptor ERalpha46 in human macrophages. PLoS One 2009, 4(5):e5539.
13. Xing D., Nozell S., Chen Y.F., Hage F., Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009, 3:289-295.
14. Calnek D.S., Mazzella L., Roser S., Roman J., Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23(1):52-57.
15. Strehlow K., Werner N., Berweiler J., Link A., Dirnagl U., Priller J., et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003, 107(24):3059-3065.
16. Besler C., Doerries C., Giannotti G., Lüscher T.F., Landmesser U. Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev Cardiovasc Ther 2008, 6(8):1071-1082.
17. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res 2011, 108(8):1002-1016.
18. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133-140.
19. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
20. Gerhard M., Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995, 92:5-8.
21. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991, 325:1196-1204.
22. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008, 102:283-294.
23. Strehlow K., Rotter S., Wassmann S., Adam O., Grohé C., Laufs K., et al. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003, 93(2):170-177.
24. O'Lone R., Knorr K., Jaffe I.Z., Schaffer M.E., Martini P.G., Karas R.H., et al. Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol Endocrinol 2007, 21(6):1281-1296.
25. Fuchtenbusch M., Standl E., Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000, 108:151-163.
26. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 2002, 277:19649-19657.
27. Schnoes K.K., Jaffe I.Z., Iyer L., Dabreo A., Aronovitz M., Newfell B., et al. Rapid recruitment of temporally distinct vascular gene sets by estrogen. Mol Endocrinol 2008, 22(11):2544-2556.
28. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613.
29. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522-529.
30. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2000, 288:321-333.
31. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998, 19:55-72.
32. Schunkert H., Danser A.H., Hense H.W., Derkx F.H., Kurzinger S., Riegger G.A. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997, 95:39-45.
33. Giltay E.J., Gooren L.J., Emeis J.J., Kooistra T., Stehouwer C.D. Oral ethinyl estradiol, but not transdermal 17ß-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost 2000, 84:359-360.
34. Rosano G.M., Vitale C., Lello S. Postmenopausal hormone therapy: lessons from observational and randomized studies. Endocrine 2004, 24(3):251-254.